Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer? immunotherapy cocktails tested in major trial

NCT ID NCT03193190

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if these combinations were safe and could shrink tumors. The trial is now complete, and results will help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atezolizumab (an immunotherapy drug) combined with standard chemotherapy drugs (nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, fluorouracil)
What this could lead to
If successful, this could point toward better treatment options for people with metastatic pancreatic cancer, potentially improving survival and quality of life.
What could go wrong
This is an early-phase study (Phase 1/2) with a small number of participants, so results may not apply to everyone. Immunotherapy combinations can cause serious side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

341 people

The number who actually took part.

Started

Jul 2017

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma * For patients in Cohort 1: no prior systemic treatment for PDAC * For patients in Cohort 2: disease progression during administration of either 5-FU- or gemcitabine-based first-line chemotherapy * Life expectancy greater than or equal to 3 months * Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing * Measurable disease (at least one target lesion) according to RECIST v1.1 * Adequate hematologic and end-organ function test results * Tumor accessible for biopsy * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm Exclusion Criteria: * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month) * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * History of leptomeningeal disease * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Positive human immunodeficiency (HIV) test at screening or at any time prior to screening * Active hepatitis B or C virus infection or active tuberculosis * Severe infection within 4 weeks prior to initiation of study treatment * Prior allogeneic stem cell or solid organ transplantation * History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Columbia University

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Helen Diller Fam Comp Can Ctr

    San Francisco, California, 94158, United States

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Hosp. G. U Gregorio Marañón

    Madrid, 28007, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28037, Spain

  • Hospital Universitario Vall d Hebron

    Barcelona, 08035, Spain

  • Kanagawa Cancer Center

    Kanagawa, 241-8515, Japan

  • Lombardi Cancer Center, Georgetown University

    Washington D.C., District of Columbia, 20007, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • MorristownMedicalCenter

    Morristown, New Jersey, 07962, United States

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, 277-8577, Japan

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut, 06510, United States

  • Uni of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • Universitätsklinikum Essen

    Essen, 45122, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.